These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 14688636

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC, Executive Steering Committee of the SPORTIFF III and V Investigators.
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [Abstract] [Full Text] [Related]

  • 3. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB, Halperin JL.
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC, Gruber M, Connolly SJ, Goldman S, Chaparro S, Vahanian A, Halinen MO, Horrow J, Halperin JL, SPORTIF Investigators.
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [Abstract] [Full Text] [Related]

  • 8. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
    Akins PT, Feldman HA, Zoble RG, Newman D, Spitzer SG, Diener HC, Albers GW.
    Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
    [Abstract] [Full Text] [Related]

  • 9. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW, SPORTIF Investigators.
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [Abstract] [Full Text] [Related]

  • 10. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB, Executive Steering Committee of the SPORTIF III Investigators.
    Lancet; 2003 Nov 22; 362(9397):1691-8. PubMed ID: 14643116
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ, Lip GY.
    Expert Rev Cardiovasc Ther; 2005 Jul 22; 3(4):551-63. PubMed ID: 16076267
    [Abstract] [Full Text] [Related]

  • 17. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H, Selçuk MT, Maden O.
    Anadolu Kardiyol Derg; 2007 Mar 22; 7(1):54-8. PubMed ID: 17347079
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.